ArticleOne health (Amsterdam, Netherlands)2025
Cross-neutralization of human sera with diverse SARS-CoV-2 omicron exposure histories, 2022-2024: Evidence of immune heterogeneity.
Article in One health (Amsterdam, Netherlands), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- SARS-CoV-2 Variants and Immune Evasion: Mapping the Future of Vaccine Design.Reviews in medical virology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: SARS-CoV-2 Omicron lineages continue to evolve, driving recurrent infection waves since 2022 through immune escape in populations with diverse immunological histories. Understanding cross-variant neutralization capacity, especially against emerging variants like JN.1, is critical for optimizing protection strategies. Methods: We conducted genomic surveillance in Jiangsu Province (December 2022-February 2024) to identify circulating variants and stratified 150 participants into six cohorts based on immune histories (BA.5/XBB breakthrough infections, JN.1 infections, and sequential exposures). Pseudovirus neutralization assays were employed to evaluate serum responses against ancestral (WT), early Omicron (BA.4/5, BF.7, BQ.1), recombinant (XBB/XBB.1.5/XBB.1.22/EG.5.1), and JN.1 variants. Results: Sera from BA.5/XBB breakthrough infections showed significantly reduced neutralization against JN.1 and EG.5.1 (vs. WT). In contrast, recent JN.1 infection induced broad-spectrum neutralization, with cross-protection comparable across variants. Sequential Omicron exposures (e.g., BA.5 → JN.1/XBB) enhanced cross-neutralization versus single infections, notably generating potent, broad antibodies even during acute phases-a previously unreported finding. Conclusions: Heterogeneous immune backgrounds necessitate vigilant monitoring of emerging variants, and sequential Omicron exposures confer robust cross-protection that can guide vaccine design and long-term public health strategies-all within a One Health framework that integrates human serosurveillance with animal and environmental monitoring to preempt cross-species transmission and future zoonotic spillover.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.